1357.1 – F-18 Fluorodeoxyglucose (FDG) positron emission tomography (PET) for the evaluation of breast cancer

New MBS item.

The proposed service is 18F-FDG PET scanning for the evaluation of breast cancer in patients who have locally advanced disease where other imaging does not provide sufficient information to determine appropriate treatment and in breast cancer patients where recurrent or metastatic disease is suspected and for whom active therapy is likely to be pursued.

Type: Investigative

Breast cancer is the most common cancer in women. In determining the best treatment for each patient, it is important to know when there is locally advanced disease, suspected recurrent breast cancer or metastatic spread. Current diagnostic methods are inferior to PET in evaluation of locally advanced disease, recurrence of disease and identification of metastatic spread. PET provides superior information to guide appropriate medical management.

• PASC meeting: -
• ESC meeting: 5 October 2018
• MSAC meeting: 22-23 November 2018